Materialise Expands Cardiovascular Capabilities through FEops Acquisition

FEops combines predictive simulation technology and artificial intelligence, allowing clinicians to more accurately predict how transcatheter structural heart devices will interact with a patient’s anatomy. Materialise’s Mimics Planner for Structural Heart Interventions, an industry-standard solution for segmentation and anatomical analysis, planning, and design, enables the creation of accurate virtual 3D models based on medical image data.

With the integration of FEops, the Mimics Planner will offer a comprehensive solution for anatomy-based 3D planning and AI-based simulation, allowing clinicians to simulate the interaction between a medical device, such as a heart valve, and a patient’s unique anatomy. This advancement is set to transform patient care for structural heart diseases by offering a more interactive and AI-based solution for preparing heart procedures.

"At Materialise, we are pioneering the advent of mass personalization in healthcare, using advanced visualization and 3D printing technologies to deliver precise, patient-specific solutions," said Brigitte de Vet, CEO of Materialise. "By integrating FEops’ advanced predictive simulation technology with our Mimics Planner, we are expanding our cardiovascular solutions to provide clinicians with comprehensive insights into patient anatomy. This integration will not only enhance the accuracy and efficiency of structural heart interventions but also improve clinical outcomes and patient safety.”

Historically, transcatheter procedures were reserved for the most complex cases and high-risk patients, but these procedures are becoming more common today. However, challenges remain in evaluating patient eligibility for transcatheter interventions and assessing potential risks and adverse events. Enhanced visualization and simulation technologies are essential in improving the clinical workflow, thereby expanding the availability of transcatheter procedures to a broader range of patients and improving overall outcomes.

Structural heart diseases, like heart valve diseases, represent a significant medical and economic challenge, being the leading cause of cardiovascular morbidity and mortality worldwide. Currently, 47 million people suffer from heart valve diseases, and this number is steadily increasing. By 2030, the annual costs associated with adverse outcomes are projected to reach 70 billion USD globally.

Materialise is advancing mass personalization in healthcare by facilitating the creation of image-based virtual 3D models for pre-procedural planning, enhancing the precision and success of complex procedures. These models enable the creation of personalized medical devices, guides, and implants tailored to the precise anatomical specifications of individual patients. This level of personalization enhances patient outcomes and makes personalized healthcare more efficient and accessible to more patients.

About Materialise

Materialise incorporates more than three decades of 3D printing experience into a range of software solutions and 3D printing services that empower sustainable 3D printing applications. Our open, secure, and flexible end-to-end solutions enable flexible industrial manufacturing and mass personalization in various industries — including healthcare, automotive, aerospace, eyewear, art and design, wearables, and consumer goods. Headquartered in Belgium and with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the world's largest and most complete 3D printing facilities

Cautionary Statement on Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our acquisition of FEops, including the benefits of the transaction, as well as statements regarding our and FEops's products, customers, and markets. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements.

These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.